In addition, genomics research retrospectively linked a variant on TNFSF13B with an augmented risk of MS and systemic lupus erythematosus (LES) and a blood increase in soluble BAFF, which is already a target of belimumab, a monoclonal antibody approved for LES (Stohl and Hilbert, 2012) and in clinical trials for MS (Steri et al., 2017). The gene discussed is TNFSF13B; the disease is myeloid sarcoma.